Personalis, Inc. (PSNL)
USD 3.3
(8.91%)
USD 3.3
(8.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.02 Million USD | 80.18% |
| 2022 | -40.47 Million USD | 23.32% |
| 2021 | -52.78 Million USD | 8.26% |
| 2020 | -57.53 Million USD | -7.18% |
| 2019 | -53.68 Million USD | -264.02% |
| 2018 | -14.74 Million USD | -188.55% |
| 2017 | -5.11 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.08 Million USD | -128.22% |
| 2024 Q1 | 3.84 Million USD | 147.88% |
| 2023 Q1 | -37.69 Million USD | 6.89% |
| 2023 Q4 | -8.02 Million USD | 75.71% |
| 2023 Q2 | -48.4 Million USD | -28.42% |
| 2023 FY | -8.02 Million USD | 80.18% |
| 2023 Q3 | -33.02 Million USD | 31.77% |
| 2022 Q3 | -34.69 Million USD | -21.68% |
| 2022 FY | -40.47 Million USD | 23.32% |
| 2022 Q1 | -31.53 Million USD | 40.26% |
| 2022 Q4 | -40.47 Million USD | -16.68% |
| 2022 Q2 | -28.51 Million USD | 9.59% |
| 2021 Q1 | -126.45 Million USD | -119.78% |
| 2021 FY | -52.78 Million USD | 8.26% |
| 2021 Q4 | -52.78 Million USD | -167.7% |
| 2021 Q3 | -19.71 Million USD | 67.97% |
| 2021 Q2 | -61.56 Million USD | 51.32% |
| 2020 Q2 | -13.7 Million USD | 69.94% |
| 2020 Q1 | -45.58 Million USD | 15.08% |
| 2020 FY | -57.53 Million USD | -7.18% |
| 2020 Q4 | -57.53 Million USD | 52.85% |
| 2020 Q3 | -122.04 Million USD | -790.72% |
| 2019 Q4 | -53.68 Million USD | 37.28% |
| 2019 Q3 | -85.59 Million USD | 40.23% |
| 2019 Q1 | -14.3 Million USD | 3.01% |
| 2019 Q2 | -143.2 Million USD | -901.14% |
| 2019 FY | -53.68 Million USD | -264.02% |
| 2018 FY | -14.74 Million USD | -188.55% |
| 2018 Q4 | -14.74 Million USD | 0.0% |
| 2018 Q1 | 22.61 Million USD | 0.0% |
| 2017 FY | -5.11 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 79.666% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | -35.643% |
| Aspira Women's Health Inc. | -331 Thousand USD | -2323.565% |
| Biodesix, Inc. | 34.3 Million USD | 123.383% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -38.407% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -545.41% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -545.41% |
| Bionano Genomics, Inc. | 34.88 Million USD | 122.998% |
| CareDx, Inc | -47.97 Million USD | 83.279% |
| Check-Cap Ltd. | -24.75 Million USD | 67.596% |
| Castle Biosciences, Inc. | -83.53 Million USD | 90.396% |
| DarioHealth Corp. | -7.54 Million USD | -6.28% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.412% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 90.284% |
| Guardant Health, Inc. | 220.22 Million USD | 103.643% |
| ICON Public Limited Company | 3.56 Billion USD | 100.225% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 101.624% |
| Illumina, Inc. | 1.21 Billion USD | 100.661% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -47.663% |
| iSpecimen Inc. | -2.14 Million USD | -273.564% |
| Standard BioTools Inc. | 46.5 Million USD | 117.249% |
| MDxHealth SA | 18.88 Million USD | 142.478% |
| 23andMe Holding Co. | -141.37 Million USD | 94.326% |
| Medpace Holdings, Inc. | -103.32 Million USD | 92.236% |
| Myriad Genetics, Inc. | 88.1 Million USD | 109.106% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 2392.95% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -228.837% |
| NeoGenomics, Inc. | 269.19 Million USD | 102.98% |
| Neogen Corporation | 735.62 Million USD | 101.09% |
| Inotiv, Inc. | 382.14 Million USD | 102.099% |
| Natera, Inc. | -200.1 Million USD | 95.991% |
| OpGen, Inc. | 11.89 Million USD | 167.458% |
| OPKO Health, Inc. | 230.68 Million USD | 103.477% |
| Psychemedics Corporation | 334 Thousand USD | 2501.796% |
| Prenetics Global Limited | -43.33 Million USD | 81.489% |
| Prenetics Global Limited | -43.33 Million USD | 81.489% |
| Precipio, Inc. | -386 Thousand USD | -1978.238% |
| RadNet, Inc. | 1.14 Billion USD | 100.698% |
| Sera Prognostics, Inc. | -2.02 Million USD | -296.736% |
| Sotera Health Company | 2.02 Billion USD | 100.396% |
| Neuronetics, Inc. | 2.79 Million USD | 386.807% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 47.695% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 47.695% |
| Trinity Biotech plc | 63.73 Million USD | 112.586% |
| T2 Biosystems, Inc. | 33.8 Million USD | 123.727% |
| Twist Bioscience Corporation | -192.4 Million USD | 95.831% |
| Exagen Inc. | -12.77 Million USD | 37.191% |